Mylan NV (MYL)

46.49
0.79 1.70
NASDAQ : Health Care
Prev Close 47.28
Open 47.13
Day Low/High 46.42 / 48.34
52 Wk Low/High 37.59 / 67.34
Volume 3.79M
Avg Volume 5.00M
Exchange NASDAQ
Shares Outstanding 508.34M
Market Cap 23.68B
EPS 1.80
P/E Ratio 29.12
Div & Yield N.A. (N.A)

Latest News

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.

Barbarian At The Gate: Mylan (MYL)

Barbarian At The Gate: Mylan (MYL)

Trade-Ideas LLC identified Mylan (MYL) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Mylan Gets EC Clearance for Meda Purchase

Mylan Gets EC Clearance for Meda Purchase

The buyer agrees to asset sales to allay the antitrust concerns of Brussels regulators.

Mylan Is Poised to Break Sideways Trend

Mylan Is Poised to Break Sideways Trend

Things are looking bullish.

Mylan Becomes #23 Most Shorted Nasdaq 100 Component, Replacing Dollar Tree

Mylan Becomes #23 Most Shorted Nasdaq 100 Component, Replacing Dollar Tree

The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Rothschild Revenue Up as it Eyes Further U.S. Investment

Rothschild Revenue Up as it Eyes Further U.S. Investment

The French bank's advisory business plans to increase its market share in the U.S.

Perrigo Sells Vitamins Business to IVC

Perrigo Sells Vitamins Business to IVC

The transaction follows a Houlihan Lokey-run sale process for the drugmaker's private-label nutraceuticals unit that was started after Mylan NV's takeover attempt was rebuffed.

Mylan To Commence Meda Offer On June 17

Mylan To Commence Meda Offer On June 17

Mylan's Offer Document Approved and Published

Perrigo Rises Further as Takeover Rumor Swirls

Perrigo Rises Further as Takeover Rumor Swirls

With no outright denial of the story to kill it, Perrigo's share rose further in Tel Aviv overnight on a day-old rumor of a $20 billion takeover deal.

Move Over Turing, Mylan May Be Next To Come Under Scrutiny

Move Over Turing, Mylan May Be Next To Come Under Scrutiny

After companies like Valeant Pharmaceuticals and Martin Shkreli's Turing Pharmaceuticals have come under heavy fire for buying medicines and then jacking up their prices, Mylan may be...

Insider Trading Alert - MYL, PKD And MDVN Traded By Insiders

Insider Trading Alert - MYL, PKD And MDVN Traded By Insiders

Stocks with insider trader activity include MYL, PKD and MDVN

Here's Why Mylan (MYL) Stock Is Surging Today

Here's Why Mylan (MYL) Stock Is Surging Today

Mylan (MYL) stock is up in late-afternoon trading on Monday after its breast cancer treatment proved comparable to a more expensive medicine by a competitor.

Mylan And Biocon To Present Phase 3 Trastuzumab Biosimilar Data At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Mylan And Biocon To Present Phase 3 Trastuzumab Biosimilar Data At The American Society Of Clinical Oncology (ASCO) Annual Meeting

HERITAGE Study Shows Comparable Efficacy, Safety and Immunogenicity to Branded Trastuzumab in HER2-Positive Metastatic Breast Cancer Patients

These 5 Stocks Look Cheap to Goldman Sachs and Have Great Charts Too

These 5 Stocks Look Cheap to Goldman Sachs and Have Great Charts Too

Goldman Sachs put together a list of 17 stocks that looked 'cheap' when considering their debt-adjusted cash flow. Here are five names that also had positive-looking charts and indicators.

17 Stocks Goldman Sachs Thinks Are Cheap Based on This One Metric

17 Stocks Goldman Sachs Thinks Are Cheap Based on This One Metric

Are you a value investor? Goldman Sachs says you may want to consider adding a company's debt-adjusted cash flow when evaluating stocks.

Mylan Launches First Generic Of Doxycycline Hyclate Delayed-Release Tablets, 50 Mg

Mylan Launches First Generic Of Doxycycline Hyclate Delayed-Release Tablets, 50 Mg

- Company awarded 180 days marketing exclusivity -